Contineum Therapeutics (CTNM) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $7.08, -10.38% vs the prior close of $7.90.
- Volume 1.11M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CTNM slides 10.4% to $7.08, a 52-week low, 5 down days in a row. Closed at $7.08, -10.38% vs the prior close of $7.90. Day range $6.95–$7.87, opened at $7.87.
CTNM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CTNM slides 10.4% to $7.08, a 52-week low, 5 down days in a row
- Closed at $7.08, -10.38% vs the prior close of $7.90. Day range $6.95–$7.87, opened at $7.87.
- Volume was 1.11M shares, 1.3x its 50-day average of 852.28K.
- Price is -49.4% vs its 50-day average ($13.98) and -48.1% vs its 200-day average ($13.64).
- 52-week range $6.95–$17.78; today's close sits at 1% of that range, 60.2% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — CTNM dips 2.9% to $7.90, a 52-week low, 4 down days in a row
- Closed at $7.90, -2.95% vs the prior close of $8.14. Day range $7.72–$8.56, opened at $8.25.
- Volume was 1.02M shares, 1.2x its 50-day average of 836.87K.
- Price is -44.2% vs its 50-day average ($14.15) and -42.2% vs its 200-day average ($13.66).
- 52-week range $7.72–$17.78; today's close sits at 2% of that range, 55.6% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — CTNM slides 3.3% to $8.14, a 52-week low, 3 down days in a row
- Closed at $8.14, -3.33% vs the prior close of $8.42. Day range $7.96–$8.80, opened at $8.21.
- Volume was 1.01M shares, 1.2x its 50-day average of 825.19K.
- Price is -43.1% vs its 50-day average ($14.30) and -40.5% vs its 200-day average ($13.68).
- 52-week range $7.96–$17.78; today's close sits at 2% of that range, 54.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CTNM dips 1.7% to $8.42, a 52-week low on 3.4x normal volume
- Closed at $8.42, -1.69% vs the prior close of $8.56. Day range $8.10–$8.94, opened at $8.56.
- Volume was 2.65M shares, 3.4x its 50-day average of 778.50K — unusually heavy trading.
- Price is -41.7% vs its 50-day average ($14.45) and -38.5% vs its 200-day average ($13.70).
- 52-week range $8.10–$17.78; today's close sits at 3% of that range, 52.7% below the 52-week high.
Oct 12, 2026 — CTNM slides 36.0% to $8.56, a 52-week low on 13.7x normal volume
- Closed at $8.56, -35.99% vs the prior close of $13.38. Day range $8.43–$11.54, opened at $9.90.
- Volume was 8.46M shares, 13.7x its 50-day average of 618.23K — unusually heavy trading.
- Price is -41.3% vs its 50-day average ($14.60) and -37.6% vs its 200-day average ($13.72).
- 52-week range $8.43–$17.78; today's close sits at 1% of that range, 51.8% below the 52-week high.
Oct 9, 2026 — CTNM rises 1.5% to $13.38, 3 up days in a row
- Closed at $13.38, +1.52% vs the prior close of $13.18. Day range $12.94–$13.85, opened at $13.17.
- Volume was 885.60K shares, 1.5x its 50-day average of 607.27K.
- Price is -9.2% vs its 50-day average ($14.74) and -2.6% vs its 200-day average ($13.74).
- 52-week range $8.60–$17.78; today's close sits at 52% of that range, 24.8% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — CTNM jumps 3.5% to $13.18 on 2.0x normal volume
- Closed at $13.18, +3.53% vs the prior close of $12.73. Day range $12.39–$13.29, opened at $12.55.
- Volume was 1.18M shares, 2.0x its 50-day average of 587.13K — unusually heavy trading.
- Price is -10.9% vs its 50-day average ($14.79) and -4.0% vs its 200-day average ($13.73).
- 52-week range $8.60–$17.78; today's close sits at 50% of that range, 25.9% below the 52-week high.
Oct 7, 2026 — CTNM rises 0.6% to $12.73
- Closed at $12.73, +0.63% vs the prior close of $12.65. Day range $12.31–$13.01, opened at $12.42.
- Volume was 707.70K shares, 1.2x its 50-day average of 577.20K.
- Price is -14.0% vs its 50-day average ($14.81) and -7.3% vs its 200-day average ($13.73).
- 52-week range $8.60–$17.78; today's close sits at 45% of that range, 28.4% below the 52-week high.
Oct 6, 2026 — CTNM dips 0.6% to $12.65
- Closed at $12.65, -0.55% vs the prior close of $12.72. Day range $12.17–$12.88, opened at $12.88.
- Volume was 761.90K shares, 1.4x its 50-day average of 564.24K.
- Price is -14.8% vs its 50-day average ($14.84) and -7.8% vs its 200-day average ($13.72).
- 52-week range $8.60–$17.78; today's close sits at 44% of that range, 28.9% below the 52-week high.
Oct 5, 2026 — CTNM slides 3.0% to $12.72
- Closed at $12.72, -3.05% vs the prior close of $13.12. Day range $12.41–$13.30, opened at $13.14.
- Volume was 508.40K shares, 0.9x its 50-day average of 556.53K.
- Price is -14.4% vs its 50-day average ($14.86) and -7.2% vs its 200-day average ($13.71).
- 52-week range $8.60–$17.78; today's close sits at 45% of that range, 28.5% below the 52-week high.
Oct 2, 2026 — CTNM rises 1.0% to $13.12
- Closed at $13.12, +1.00% vs the prior close of $12.99. Day range $12.59–$13.24, opened at $13.15.
- Volume was 794.30K shares, 1.5x its 50-day average of 543.37K.
- Price is -11.9% vs its 50-day average ($14.89) and -4.3% vs its 200-day average ($13.71).
- 52-week range $8.60–$17.78; today's close sits at 49% of that range, 26.2% below the 52-week high.
CTNM latest news & SEC filings
Every SEC filing by or about CTNM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Stengone Carmine N. sold 2,500 shares at $16.46 (≈$41.15K) on Sep 8, 2026
- Stengone Carmine N. sold 2,500 shares at $16.46 (≈$41.15K) on Sep 8, 2026
- Stengone Carmine N. sold 2,500 shares at $16.46 (≈$41.15K) on Sep 8, 2026
- Stengone Carmine N. sold 2,500 shares at $16.46 (≈$41.15K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Stengone Carmine N. sold 2,500 shares at $16.01 (≈$40.03K) on Aug 3, 2026
- Stengone Carmine N. sold 2,500 shares at $16.01 (≈$40.03K) on Aug 3, 2026
- Stengone Carmine N. sold 2,500 shares at $16.01 (≈$40.03K) on Aug 3, 2026
- Stengone Carmine N. sold 2,500 shares at $16.01 (≈$40.03K) on Aug 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 3, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$15.15M (prior year -$16.04M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.40 (prior year -$0.62) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 17, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade CTNM
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Mar 5, 2026, Oct 30, 2025. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.21% (largest 36.0%). That is a volatile stock.
- Liquidity: about 1.29M shares (≈$9.15M) trade per day on average.
- 52-week position: $7.08 vs a range of $6.95–$17.78 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Carmine N. Stengone sold 2,500 shares on Sep 8, 2026.
- Latest filings: 8-K Sep 14, 2026; 10-Q Jul 30, 2026; 8-K Jul 30, 2026.
- Share count: 23.10M shares outstanding (Oct 27, 2025), +21.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CTNM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.87 | 7.87 | 6.95 | 7.08 | 1.11M |
| Oct 15, 2026 | 8.25 | 8.56 | 7.72 | 7.90 | 1.02M |
| Oct 14, 2026 | 8.21 | 8.80 | 7.96 | 8.14 | 1.01M |
| Oct 13, 2026 | 8.56 | 8.94 | 8.10 | 8.42 | 2.65M |
| Oct 12, 2026 | 9.90 | 11.54 | 8.43 | 8.56 | 8.46M |
| Oct 9, 2026 | 13.17 | 13.85 | 12.94 | 13.38 | 885.60K |
| Oct 8, 2026 | 12.55 | 13.29 | 12.39 | 13.18 | 1.18M |
| Oct 7, 2026 | 12.42 | 13.01 | 12.31 | 12.73 | 707.70K |
| Oct 6, 2026 | 12.88 | 12.88 | 12.17 | 12.65 | 761.90K |
| Oct 5, 2026 | 13.14 | 13.30 | 12.41 | 12.72 | 508.40K |
| Oct 2, 2026 | 13.15 | 13.24 | 12.59 | 13.12 | 794.30K |
| Oct 1, 2026 | 13.30 | 13.50 | 12.62 | 12.99 | 774.00K |
| Sep 30, 2026 | 11.59 | 13.55 | 11.59 | 13.42 | 1.60M |
| Sep 29, 2026 | 12.83 | 13.09 | 10.84 | 11.50 | 854.90K |
| Sep 28, 2026 | 12.38 | 13.36 | 11.95 | 12.73 | 534.10K |
| Sep 25, 2026 | 12.57 | 12.88 | 12.10 | 12.56 | 404.90K |
| Sep 24, 2026 | 12.49 | 12.74 | 11.40 | 12.49 | 632.20K |
| Sep 23, 2026 | 13.33 | 13.33 | 12.44 | 12.51 | 550.30K |
| Sep 22, 2026 | 13.74 | 14.00 | 13.19 | 13.40 | 770.30K |
| Sep 21, 2026 | 13.69 | 13.89 | 13.44 | 13.55 | 638.50K |
About Contineum Therapeutics
Contineum Therapeutics (CTNM) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1855175.
CTNM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sarah Boyce | Director | Jun 26, 2026 |
| Todd R. Brady | Director | Jun 26, 2026 |
| Troy A. Ignelzi | Director | Jun 26, 2026 |
| Lori Lyons-Williams | Director | Jun 26, 2026 |
| Gines Diego Miralles | Director | Jun 26, 2026 |
| Evert B. Schimmelpennink | Director | Jun 26, 2026 |
| Carmine N. Stengone | CEO and President | Sep 8, 2026 |
| Olivia C Ware | Director | Jun 26, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John Stephen Healy | General Counsel and Corp Sec | Jan 30, 2026 |
| Daniel S. Lorrain | Chief Scientific Officer | Jul 10, 2026 |
| Peter T Slover | Chief Financial Officer | Jan 30, 2026 |
| Carmine N. Stengone | CEO and President | Sep 8, 2026 |
| Tim Watkins | CMO & Head of Development | Jul 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengone | Sale | 2,500 | $16.46 |
| Sep 8, 2026 | Carmine N. Stengone | Sale | 2,500 | $16.46 |
| Sep 8, 2026 | Carmine N. Stengone | Sale | 2,500 | $16.46 |
| Sep 8, 2026 | Carmine N. Stengone | Sale | 2,500 | $16.46 |
| Aug 3, 2026 | Carmine N. Stengone | Sale | 2,500 | $16.01 |
| Aug 3, 2026 | Carmine N. Stengone | Sale | 2,500 | $16.01 |
| Aug 3, 2026 | Carmine N. Stengone | Sale | 2,500 | $16.01 |
| Aug 3, 2026 | Carmine N. Stengone | Sale | 2,500 | $16.01 |
| Jul 9, 2026 | Daniel S. Lorrain | Sale | 25 | $16.00 |
| Jul 9, 2026 | Daniel S. Lorrain | Sale | 25 | $16.00 |
| Jul 9, 2026 | Daniel S. Lorrain | Sale | 25 | $16.00 |
| Jul 9, 2026 | Daniel S. Lorrain | Sale | 25 | $16.00 |
| Jul 8, 2026 | Daniel S. Lorrain | Sale | 1,015 | $16.00 |
| Jul 8, 2026 | Daniel S. Lorrain | Sale | 1,015 | $16.00 |
| Jul 8, 2026 | Daniel S. Lorrain | Sale | 1,015 | $16.00 |
CTNM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-59.98M | -2.17 | $-55.31M |
| Dec 31, 2024 | $0 | $-42.26M | -2.18 | $-32.84M |
| Dec 31, 2023 | $50.00M | $22.72M | 0.08 | $19.35M |
Latest balance sheet: total assets $250.37M, total liabilities $10.71M, cash $14.71M (as of Jun 30, 2026).
CTNM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $15.75 |
| May 5, 2026 | 8-K Item 2.02 (results) | $14.39 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $13.81 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $10.54 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $6.00 |
| May 14, 2025 | 8-K Item 2.02 (results) | $3.84 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $6.44 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $17.24 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 16, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CTNM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.